title: Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
authors.forename: Pinar
authors.initials: P
authors.lastname: Oztas
authors.forename: Servet
authors.initials: S
authors.lastname: Erbasi
authors.forename: Nurdan
authors.initials: N
authors.lastname: Lenk
authors.forename: Muhterem
authors.initials: M
authors.lastname: Polat
authors.forename: Ozge
authors.initials: O
authors.lastname: Han
authors.forename: Ferda
authors.initials: F
authors.lastname: Artuz
authors.forename: Nuran
authors.initials: N
authors.lastname: Alli
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides; D003873:Dermatitis, Exfoliative / Q000139:chemically induced*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate